Neogenomics (NEO) Operating Income (2010 - 2026)

Neogenomics (NEO) has 17 years of Operating Income data on file, last reported at -$9.8 million in Q2 2026.

• Quarterly Operating Income rose 79.48% year-over-year to -$9.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$68.4 million (up 40.51% YoY) and the FY2025 annual result came in at -$115.9 million, down 25.81% from the prior year.
• Operating Income advanced to -$9.8 million in Q2 2026, from -$18.2 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$9.8 million in Q2 2026 to a low of -$52.0 million in Q1 2022.
• A 5-year average of -$27.9 million and a median of -$26.7 million in 2022 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2022 — Operating Income slumped 244.4% — and 2026, when it surged 79.48%.
• Tracing NEO's Operating Income over 5 years: stood at -$26.4 million in 2022, then grew by 29.6% to -$18.6 million in 2023, then grew by 0.93% to -$18.4 million in 2024, then grew by 27.1% to -$13.4 million in 2025, then increased by 27.16% to -$9.8 million in 2026.
• The last three Operating Income figures came in at -$9.8 million (Q2 2026), -$18.2 million (Q1 2026), and -$13.4 million (Q4 2025), per Business Quant data.